
BCAX Stock Forecast & Price Target
BCAX Analyst Ratings
Bulls say
Bicara Therapeutics Inc is positioned positively in the biopharmaceutical sector, particularly with its lead program, ficerafusp alfa, demonstrating a significantly higher objective response rate (ORR) compared to established therapies such as Keytruda, highlighting its potential efficacy in treating solid tumors. The treatment also shows promising metrics with a median progression-free survival (mPFS) of 9.9 months and a median overall survival (mOS) of 21.3 months, which surpass traditional benchmarks observed in similar patient populations. These advancements suggest a robust therapeutic profile that could drive future growth and valuation for the company as clinical results progress.
Bears say
Bicara Therapeutics reported a net loss of $0.50 per share for the second quarter of 2025, consistent with prior estimates of a $0.51 loss, indicating a lack of operational improvement. The company faces several risks, including potential negative clinical outcomes with its lead therapy, ficerafusp alfa, and the possibility of delays in moving into registrational trials, which could hinder its development timeline. Furthermore, projected full-year losses for 2025 are anticipated at $2.27 per share, slightly better than previous estimates, yet still reflecting ongoing financial challenges and uncertainties in achieving regulatory approvals and overcoming competitive pressures.
This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
BCAX Analyst Forecast & Price Prediction
Start investing in BCAX
Order type
Buy in
Order amount
Est. shares
0 shares